Skip to Content
Stock Strategist Industry Reports

Will Vaccine Transport Boost the Industrial Cold-Chain Opportunity?

The market is warm to the idea, but we don't see a meaningful long-term impact for companies in this space.

Mentioned: , ,

The biopharmaceutical cold chain is mission-critical in ensuring that vaccines are delivered from the point of manufacturing to the consumer. However, a lack of adequate equipment is a recurring problem in the cold chain, with few countries having suitable ultracold infrastructure in place to meet any surge in demand for vaccines.

Joshua Aguilar does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.